FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents antibodies which bind programmed human cell 1 protein (PD-1) protein.
EFFECT: these antibodies can be useful for treating cancer alone and in combination with chemotherapy and other cancer treatment agents.
35 cl, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO PD-1 AND COMPOSITIONS | 2016 |
|
RU2750675C1 |
| ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2736720C2 |
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND OPTIONS OF THEIR USE | 2019 |
|
RU2812765C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
| ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS FOR USE THEREOF | 2016 |
|
RU2729379C1 |
| PD-1 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2722451C1 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
